DEA • Controlled Substances • Drug Supply • Pharmacy Operations

DEA’s Higher 2026 Production Quotas Take Effect

DEA’s final order took effect November 10 when it appeared in the Federal Register. It raises the national production quotas for two amphetamine categories, hydromorphone, and methylphenidate for sale. The published figures match the order made available for public inspection on November 9. DEA separately published proposed 2027 quotas, with comments due December 10 at 11:59 p.m. Eastern for electronic filings. The higher 2026 limits allow additional production. Pharmacy teams can track whether availability improves by strength, package, and supplier.

By Toby C. “Chad” Frost • November 10, 2026
1 min read

The final 2026 order

DEA signed the final order on November 4 and filed it for public inspection November 9. The Federal Register published the order November 10 and the adjustments took effect that day. The order raises the 2026 aggregate production quotas to 31,654,915 grams for d,l-amphetamine, 37,108,041 grams for d-amphetamine for sale, 2,356,798 grams for hydromorphone, and 69,502,651 grams for methylphenidate for sale. DEA cites FDA shortage listings for mixed amphetamine salts tablets, hydromorphone injection, and methylphenidate tablets and film.1

The 2027 proposal

DEA published a separate notice on November 10 proposing 2027 aggregate quotas. Electronic comments are due by 11:59 p.m. Eastern on December 10, 2026. Written comments must be postmarked by December 10. DEA will establish the 2027 figures in a later final order.2

What to track in purchasing

Treat the higher limits as a supply signal. Confirm availability by strength, dosage form, and package with the wholesaler before changing reorder levels or giving a patient a pickup estimate. Track the products your pharmacy actually dispenses so you can tell when allocations or backorders improve.

Source notes

  1. Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h), 91 Fed. Reg. 72,564, 72,564–66 (Nov. 10, 2026).
  2. Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027, 91 Fed. Reg. 72,566, 72,566–67 (Nov. 10, 2026).